Bimatoprost
Brand names: Bimatoprost, Durysta, Lumigan
At a glance
- Medicare prescriptions, 2024
- 1,289,098
- Medicare drug cost
- $582.8M
- Average cost per prescription
- $452
- Clinicians who prescribed it
- 20,433
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
LUMIGAN ® (bimatoprost ophthalmic solution) 0.01% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
From the FDA-approved prescribing information (label dated June 2024). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Ophthalmology 68.9%
- Optometrists 25.0%
- Internal Medicine 1.6%
- Family Medicine 1.2%
- Nurse Practitioners 0.9%
- Retina Specialist 0.8%
- General Practice 0.6%
- Physician Assistants 0.3%
- Geriatric Medicine 0.3%
- Hospitalist 0.0%
- Cardiology 0.0%
- Hospice & Palliative Medicine 0.0%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 17% from 2019 to 2024.
Biggest change by state since 2019
- Puerto Rico +23%
- Michigan +2%
- Oklahoma −6%
- Alabama −7%
- Mississippi −9%
- Nebraska (smallest change) −38%
- South Dakota (smallest change) −37%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
Industry payments about this drug
Drug makers reported $2.2M in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- AbbVie Inc. $2.2M
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Industry-funded trials
- Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension Completed · AbbVie Inc.
- Long-term Safety and Efficacy Extension Trial of Bimatoprost SR Completed · AbbVie Inc.
- 18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA) Completed · AbbVie Inc.
- Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension Completed · AbbVie Inc.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.